Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036959 · ClinicalTrials.gov registry record · Phase 1
ABT-751 in Treating Young Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT00036959 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 90 participants.
The verdict
NCT00036959, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.
Interventions
- DRUG ABT-751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2002-03 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036959
The ClinicalTrials.gov registry entry for NCT00036959 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-751 is the first listed.
NCT00036959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036959 about?
NCT00036959 is a clinical study titled "ABT-751 in Treating Young Patients With Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.
What is the current status of trial NCT00036959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2002-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00036959?
The interventions under investigation include: ABT-751 (DRUG).
Who is sponsoring clinical trial NCT00036959?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.